51¸£Àû

Broken String Biosciences, today announced the submission of a Master File (MAF) to the U.S. Food and Drug Administration (FDA) for its INDUCE-seq® platform, marking a significant step in supporting regulatory adoption of genome-wide DNA break analysis in gene editing programs. 

Alongside rebranding, we have redesigned our website so researchers can easily access a comprehensive resource library and gain a clear understanding of how our INDUCE-seq platform can be applied across gene editing workflows to maximize value in development pipelines.

To drive the company’s commercial expansion, Terry Pizzie has been appointed as CEO, bringing extensive experience from leading and scaling global life science businesses.

Broken String’s participation in the NIST Genome Editing Consortium is part of the company’s efforts to shape industry-wide safety standards for emerging genome editing technologies, including CRISPR, base editing, and prime editing.

Powered by gene editing advances like CRISPR and base editing, cell and gene therapy (CGT) is delivering on the promise of genomic medicine. First-generation CAR T-cell therapies, for example, have been functional cures for many patients with otherwise untreatable hematologic cancers.

51¸£Àû, a leader in advancing gene editing safety, and BioLizard, an expert in scientific data analytics and AI, today announced the development of SafeGuide, an AI tool for selecting safer, better guide RNAs (gRNA), the gene editing element that tells tools like CRISPR where to repair DNA.

Over the last decade, dozens of efforts have applied machine learning, deep learning, and other models for various CRISPR-related activities, mostly in attempts to predict on- and off-target activity. For the latter, accurate off-target predictions would be a powerful tool for safety assessment, given that opacity has already raised questions leading to clinical holds by FDA.

Broken String’s INDUCE-seq® platform will be used as a first-of-its-kind offering for rapidly detecting on-target and off-target effects that can occur during gene editing. This new on-demand offering enables gene editing therapy developers to assess on- and off-target effects in days, as opposed to months.

51¸£Àû announces the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) to its Board of Directors. 

51¸£Àû announces the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) to its Board of Directors.